Latest Industry Insights

Explore the current understanding from the scientific literature on how protein misfolding, mislocalization and malfunction can lead to Alzheimer's disease.

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn about the challenges in non-small cell lung cancer treatment and how proteomics-based analysis could enable personalized cancer treatments.

In this interview, Technology Networks spoke to Heiko Neuweger, director of Bioinformatics Life Science Mass Spectrometry Software R&D at Bruker, to learn about the importance of target compound annotation and identification, the advantages of integrating collision cross section (CCS) information into workflows and the benefits of CCS-Predict Pro.

Join us for an interview with HP's Christie Dudenhoefer, manager of Life Science Solutions, and Dr. Ryan Kelly, professor in the Department of Chemistry at Brigham Young University, to learn how HP's D100 single-cell dispenser is being utilized.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.